Snider Financial Group Sells 3,538 Shares of Veeva Systems Inc. $VEEV

Snider Financial Group trimmed its stake in shares of Veeva Systems Inc. (NYSE:VEEV) by 16.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,498 shares of the technology company’s stock after selling 3,538 shares during the quarter. Veeva Systems accounts for 1.3% of Snider Financial Group’s holdings, making the stock its 26th largest holding. Snider Financial Group’s holdings in Veeva Systems were worth $5,280,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of VEEV. SHP Wealth Management acquired a new stake in Veeva Systems in the 4th quarter valued at about $26,000. Compass Financial Management LLC acquired a new position in shares of Veeva Systems during the second quarter worth about $27,000. Burkett Financial Services LLC acquired a new position in shares of Veeva Systems during the third quarter worth about $27,000. Arlington Trust Co LLC purchased a new stake in shares of Veeva Systems during the second quarter worth approximately $29,000. Finally, Field & Main Bank purchased a new stake in shares of Veeva Systems during the second quarter worth approximately $29,000. Hedge funds and other institutional investors own 88.20% of the company’s stock.

Veeva Systems News Roundup

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: IQVIA selected Veeva’s clinical software as an enterprise standard. IQVIA will use Veeva Clinical Trial Management System, eTMF, Study Startup, and Site Connect across its global research operations. The agreement expands Veeva’s role in IQVIA’s clinical workflow, strengthens its position with contract research organizations and biopharma customers, and could support recurring revenue growth. Veeva Systems Becomes Default Clinical Software Across a Major Research Partner
• Positive Sentiment: Technical momentum and institutional interest have accelerated. Reports said Veeva broke above a buy point as “big money” added exposure to the company’s AI-related software opportunity. Shares subsequently reached a fresh 52-week high and posted sizable single-session gains, attracting additional momentum-oriented investors. Veeva Stock Breaks Out As Big Money Grabs Exposure To The AI Software Play
• Positive Sentiment: Analyst coverage remains favorable. Oppenheimer maintained a $325 price target, while the average Wall Street recommendation remains positive. These views reinforce the market’s expectation that Veeva can continue expanding despite a potential moderation in research-and-development growth. Oppenheimer Keeps $325 Target for Veeva Systems Stock
• Neutral Sentiment: More than 175 emerging biotechs are reportedly using Veeva Basics, indicating continued adoption of the company’s broader cloud software platform. However, the immediate financial impact was not quantified. Veeva’s Clinical Technology Moat and IQVIA Deal
• Negative Sentiment: Senior Vice President Jonathan Faddis sold 5,198 shares for approximately $1.56 million, reducing his direct ownership by 55.7%. The transaction occurred under a pre-arranged Rule 10b5-1 plan, which limits its significance as a discretionary bearish signal, but insider selling can still temper enthusiasm after a strong rally. SEC Insider Transaction Filing

Wall Street Analyst Weigh In

VEEV has been the topic of several analyst reports. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $330.00 target price on shares of Veeva Systems in a report on Tuesday, September 8th. Wall Street Zen upgraded shares of Veeva Systems from a “hold” rating to a “buy” rating in a research note on Saturday, October 10th. Stifel Nicolaus set a $300.00 price target on shares of Veeva Systems in a report on Thursday, August 27th. Jefferies Financial Group reissued a “buy” rating and issued a $295.00 price objective on shares of Veeva Systems in a research report on Thursday, August 27th. Finally, Guggenheim raised their price objective on shares of Veeva Systems from $276.00 to $310.00 and gave the company a “buy” rating in a report on Thursday, August 27th. Nineteen research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Veeva Systems currently has a consensus rating of “Moderate Buy” and an average target price of $285.92.

Insider Activity at Veeva Systems

In related news, EVP Daniel J. Rizzo sold 4,841 shares of the stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $276.51, for a total value of $1,338,584.91. Following the transaction, the executive vice president directly owned 7,665 shares of the company’s stock, valued at $2,119,449.15. This trade represents a 38.71% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Thomas D. Schwenger sold 10,000 shares of Veeva Systems stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $281.33, for a total transaction of $2,813,300.00. Following the sale, the insider owned 19,449 shares in the company, valued at $5,471,587.17. This represents a 33.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 56,789 shares of company stock worth $14,913,889 over the last 90 days. 10.60% of the stock is owned by corporate insiders.

Veeva Systems Stock Performance

NYSE VEEV traded down $2.13 during trading on Friday, reaching $310.90. 1,730,063 shares of the company’s stock were exchanged, compared to its average volume of 1,686,745. The stock has a market cap of $50.34 billion, a P/E ratio of 51.14, a price-to-earnings-growth ratio of 1.34 and a beta of 0.93. The company has a 50 day moving average price of $269.81 and a two-hundred day moving average price of $207.95. Veeva Systems Inc. has a 1 year low of $148.05 and a 1 year high of $319.95.

Veeva Systems (NYSE:VEEV) last released its quarterly earnings data on Wednesday, August 26th. The technology company reported $2.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.23 by $0.12. Veeva Systems had a return on equity of 14.25% and a net margin of 29.34%. The business had revenue of $927.96 million during the quarter, compared to analysts’ expectations of $905.38 million. During the same period in the prior year, the firm posted $1.99 EPS. The business’s quarterly revenue was up 17.6% compared to the same quarter last year. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. Research analysts forecast that Veeva Systems Inc. will post 6.70 EPS for the current fiscal year.

Veeva Systems Profile

Veeva Systems Inc is a cloud software company that provides applications and services for the life sciences industry. Its customers include pharmaceutical, biotechnology, medical device and other organizations involved in developing, manufacturing and commercializing regulated products.

The company’s product portfolio includes the Veeva Vault platform, which supports areas such as clinical operations, regulatory affairs, quality management, safety and medical communications. Veeva also offers commercial and customer relationship management applications, data and analytics products, and services designed to help life sciences companies manage relationships with healthcare professionals, oversee content and improve operational efficiency.

Founded in 2007, Veeva serves customers globally and has expanded its offerings from commercial software into research, development, manufacturing and quality processes.